BUILDING WORKPLACE TRUST ‘MORE IMPORTANT THAN EVER’: International HR Day focuses on four key topics under theme of ‘Shaping the New Future’

The organisers of International HR Day say business leaders need to be supported in building high trust cultures now more than ever, given the disruption being seen around the world. This year marks the fifth International HR Day, which is organised by the European Association for People Management (EAPM)  to celebrate how the HR and […]

Continue Reading

WebAccountPlus Announces Partnership with Leading Global Fintech Influencer and Best-Selling Author, Chris Skinner, to Join Advisory Board and Become Shareholder

WebAccountPlus, the pioneering digital corporate advisor and world’s first ecosystem for small and medium-sized enterprises (SMEs), banks, trustees, insurance companies, fiduciaries, corporate and wealth advisors, is thrilled to announce the addition of Chris Skinner to its advisory board and as a shareholder of the company. Recognized as one of the most influential figures in fintech, banking and technology, Skinner brings a wealth of expertise and insight to WebAccountPlus.   Skinner, a visionary leader in the fintech sector, is known for his pioneering work in the formation of one of the world’s first mobile banks and his role as an independent commentator on financial markets through his popular blog, the Finanser.com. He has advised CEOs and leaders from every continent of the world including the United Nations, the White House, the World Bank and the World Economic Forum. His latest book, Digital for Good, exemplifies his belief in the power of technology and finance to address today’s environmental and social issues. As a visiting lecturer at Cambridge University and a TEDx speaker, Skinner has disseminated his insights to a global audience, cementing his reputation as a leading authority in the field.   “We are excited to have Chris Skinner join our advisory board and become a shareholder,” said Roland Staehli, CEO of WebAccountPlus. “His unparalleled expertise and progressive style in digital transformation and the financial technology sector will bring an invaluable perspective to our platform. With his involvement, we are confident in our ability to revolutionize the banking advisory and fiduciary business.”   Skinner also shared his enthusiasm about joining WebAccountPlus’s advisory board: “I’m delighted to contribute to the transformative work of WebAccountPlus. Their commitment to leveraging artificial intelligence in the banking and fiduciary industry aligns perfectly […]

Continue Reading

ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced its first quarter 2023 financial results and recent highlights.   Received FDA clearance […]

Continue Reading

How to find the right SMS Platform?

The messaging industry is changing so rapidly. Not so long ago, there was an assumption that social networks and messaging applications would soon take over as the primary mode of communication, and push SMS aside. The prospect of younger generations abandoning traditional communication methods such as SMS, voice calls and emails for social media sites […]

Continue Reading

3 Ways to Celebrate Mother’s Day with BLUETTI

Mother’s Day is an occasion to show love and appreciation to our mothers and mother figures. This year, BLUETTI is offering a promotion from May 6th to 18th to help make Mother’s Day extra special. Here are three ways to celebrate with BLUETTI power solutions.   1. Spoil Mom with a Relaxing Excursion   Planning a camping […]

Continue Reading

ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease

ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) […]

Continue Reading